miR-7: An anti-cancer micro RNA
miReven is a biopharmaceutical company focused on developing miR-7 as a cancer therapy. The Company was formed in 2010 through an investment from the Medical Research Commercialisation Fund (MRCF). The Company’s published research shows that miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor (EGFR), as well as its associated signaling pathways that promote cancer development. EGFR is a major target for cancer therapy because it is often associated with disease progression, resistance to chemotherapy and radiation therapy. WAIMR is assisted in the commercialisation of its intellectual property by the University of Western Australia, through its Office of Industry and Innovation.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Of Industry And Innovation.
- Phone
- 61 3 9657 0700
- in****@****.com.au
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- mireven.com.au
- Keywords
- Scarborough.
Mireven Pty Ltd Questions
Mireven Pty Ltd's helpline number is 61 3 9657 0700
Mireven Pty Ltd's website is mireven.com.au
Mireven Pty Ltd's LinkedIn profile is https://au.linkedin.com/company/mireven-pty-ltd
Mireven Pty Ltd has
3 employees.
View email and phone details for 3
employees at Mireven Pty Ltd.
Mireven Pty Ltd's industry is
Pharmaceutical Manufacturing
Mireven Pty Ltd's top competitors are
Planfarm,
Wafarmers,
Resseptor Therapeutics,
The Ceo Institute Wa,
Electro Ventures,
Athena Medicines,
Otifex Therapeutics,
Quest Biotech Pharma,
Mycrx,
Breast Cancer Care Wa.
Mireven Pty Ltd's support email address is info@mireven.com.au
Mireven Pty Ltd's categories are Pharmaceutical Manufacturing
Mireven Pty Ltd's founding year is 2010
